Short Summary
Azurity Pharmaceuticals has filed an IPR petition seeking cancellation of claims 1‑3 of Exelixis’s U.S. Pat. 11,298,349 covering oral cabozantinib (L)-malate formulations. The petition alleges anticipation by the earlier Wilson patent and obviousness over Brown, Kubo and Remington, while arguing that discretionary denial factors do not apply.
Detailed Summary
In a petition for inter‑partes review of U.S. Patent 11,298,349, Azurity Pharmaceuticals challenges claims 1‑3 that claim broad oral tablet or capsule formulations of cabozantinib (L)-malate that are essentially free of process by‑products or the impurity 6,7‑dimethoxy‑quinoline‑4‑ol. The challenger asserts two statutory grounds: (1) anticipation under 35 U.S.C. §102 by the earlier Wilson patent, which discloses a species falling within the claimed genus; and (2) obviousness under 35 U.S.C. §103 over Brown in view of Kubo and the Remington textbook, arguing that the combination of known excipients and a one‑step synthetic route would have been obvious. The petition also contends that the claims lack written‑description support for the broad excipient categories and that all Fintiv discretionary factors and the Advanced Bionics test disfavor denial of institution. No settlement or dismissal is indicated, and the proceeding remains at the petition stage awaiting institution.
Practitioner Note
This case demonstrates the evidentiary and procedural standards applied in patent matters before local courts. Understanding the court's reasoning in Azurity Pharmaceuticals, Inc. vs EXELIXIS, INC. is valuable context for structuring arguments or assessing risk in similar proceedings.
Related Cases
Wealth, Inc.vs--
Wealth, Inc. has filed a Post‑Grant Review petition seeking cancellation of all 20 claims of Vanilla Technologies’ U.S. Patent 12,353,917, alleging ineligibility, obviousness, indefiniteness, and an improper dependent claim. The petition relies on prior‑art references Racanelli, Bateman, Dintenfass, McMillen and Kwak.
Microsoft CorporationvsQomplx LLC
Microsoft has filed an IPR petition challenging 16 claims of Qomplx’s U.S. Patent 12,301,627 covering graph‑based network anomaly detection. The challenger asserts obviousness over prior‑art references Stokes, Crabtree, and Sekar under 35 U.S.C. §103.
Microsoft CorporationvsToutVirtual, Inc.
Microsoft has filed an IPR petition challenging all 20 claims of ToutVirtual’s ‘667 patent covering virtual system management, asserting obviousness over multiple prior‑art references.
Cisco Systems, Inc.vsGOLDEN EYE TECHNOLOGIES LLC
Cisco has filed an IPR petition seeking to invalidate claims 1‑3 and 13‑15 of Golden Eye Technologies' 9,717,037 patent. The challenger argues the claims are obvious over earlier Wi‑Fi standards and patents (Choudhary, Hasty, Chen). The petition requests the Board to institute the review and cancel the challenged claims.
Cisco Systems, Inc.vsGolden Eye Technologies LLC
Cisco has filed an IPR petition seeking to invalidate claims 1‑4 and 9‑11 of Golden Eye’s ’556 Wi‑Fi scanning patent, arguing that the claims are obvious over three earlier patents. The petition emphasizes that the patent was allowed despite acknowledging the same prior‑art concepts.
Pinterest, Inc.vs--
Pinterest has filed an IPR petition challenging all 20 claims of OpenTV’s ’703 patent, asserting that the claims are obvious over prior art such as Orr, Hsu, Lim, and Hervey.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.
Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.